Brought to you by 
Nuvectra closes $64.9mm FOPO
17 Sep 2018
Executive Summary
Nuvectra Corp. (neuromodulation devices) netted $64.9mm in a public offering of 3.2mm shares (including the overallotment) at $21.25. The company will use the proceeds to expand product development and commercialization. Nuvectra is awaiting CE Mark and PMA approval for its Virtis sacral nerve stimulation (SNS) device for urinary incontinence and overactive bladder. In July, both EU and US agencies informed Nuvectra that additional clinical study data would be required before recommending approval, but the company still anticipates product launches by the end of the year (EU) and during 1H 2019 (US).
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nuvectra closes $64.9mm FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice